dsip peptide

DSIP peptide  (Delta Sleep-Inducing Peptide) is a structurally short neuropeptide of natural origin that influences a number of endocrine as well as physiological processes in the central nervous system. It was first isolated in 1970s from cerebral venous blood of rabbit brains during slow-wave sleep. It is of great interest for its effects and ability to induce sleep, especially in chronic insomnia, release pain, reduce oxidative stress, enhance muscle building, normalize of myocardial contractility, and is also being investigated as a possible agent in the treatment of depressive disorder and withdrawal symptoms. In human research of chronic insomniacs DSIP had normalizing influence on sleep regulation DSIP peptide  .

DSIP stands for **Dopamine System Instability Protein**. It’s a protein involved in the dopamine system in the brain, specifically with the regulation of dopamine signaling.

While research is ongoing, the precise function and role of DSIP are still being investigated. Current understanding suggests it may be involved in:

* **Dopamine signaling modulation:** This likely involves interaction with dopamine receptors or other proteins in the dopamine pathway.
* **Synaptic plasticity:** The process of strengthening or weakening connections between neurons, which is crucial for learning and memory.
* **Neuroprotection:** Potentially protecting neurons from damage, though more research is needed to confirm this.

DSIP is a relatively newly discovered protein and more research is needed to fully understand its role in the complex interplay of the nervous system.

Delta sleep-inducing peptide (DSIP) is a naturally occurring substance, which was originally isolated from rabbit brain in 1977 [¹]. This curious substance is a nonapeptide that is normally synthesized in the hypothalamus and targets multiple sites including some within the brainstem [²]. As its name suggests DSIP promotes sleep and this has been demonstrated in rabbits, mice, rats, cats and human beings [^3–5]. In fact DSIP promotes a particular type of sleep which is characterized by an increase in the delta rhythm of the EEG.

DSIP

DSIP is normally present in minute amounts in the blood. Brain and plasma DSIP concentrations exhibit a marked diurnal variation [⁶] and there has been shown to be a correlation between DSIP plasma concentrations and circadian rhythm in human beings. Concentrations are low in the mornings and higher in the afternoons. An elevation of endogenous DSIP concentration has been shown to be associated with suppression of both slow-wave sleep and rapid-eye-movement sleep and interestingly also with body temperature [⁷]. Plasma concentrations of DSIP are influenced by the initiation of sleep [⁸]. Patients with Cushing’s syndrome suffer from a lack of slow-wave sleep but the diurnal variation in slow-wave and rapid-eye-movement sleep in those patients appears to be similar to that in normal patients [⁹].

DSIP has been synthesized. Administration of the synthetic substance does not induce tolerance [¹³]. DSIP can be assayed by several techniques including radioimmunoassay (RIA), enzyme immunoassay and high-performance liquid chromatography with RIA [^14–16]. DSIP has a half-life in human plasma of between 7 and 8 min [²]. It is degraded in blood, the pathway involving the amino-peptidases [¹⁷]. A potential drug interaction might therefore be envisaged between DSIP and drugs which inhibit or are themselves metabolized by peptidases. Captopril is one such agent and patients currently undergoing treatment with any of the angiotensin-converting enzyme inhibitors should probably be excluded from any DSIP treatment protocol until further studies have been undertaken.